Trials / Terminated
TerminatedNCT04117477
Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients
Healthcare Associated Infection Reduction in Stem Cell Transplant Patients: a Randomized, Double-blind, Placebo-controlled Study Evaluating Twice Daily Xylitol Administration
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Children's Hospital Medical Center, Cincinnati · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The central hypothesis is that daily dental xylitol wipes, in addition to current oral care practice, are effective at reducing BSI from oral organisms, and decreasing the incidence of gingivitis, oral plaque, and oral ulcerations after SCT.
Detailed description
Our long-term goal is to develop and disseminate clinically relevant, and easily adoptable strategies to prevent BSI and improve outcomes after SCT. The overall objective of this proposal is to identify a clinically effective strategy to prevent or reduce BSI secondary to bacterial translocation through oral injured mucosa .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xylitol | Xylitol dental wipes |
| OTHER | Placebo | Placebo dental wipes |
Timeline
- Start date
- 2019-09-27
- Primary completion
- 2021-03-20
- Completion
- 2021-03-20
- First posted
- 2019-10-07
- Last updated
- 2023-02-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04117477. Inclusion in this directory is not an endorsement.